Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
New study focuses on treatment, resources, and impact of atopic dermatitis
Washington -- A recent prospective study has shown that treatment of atopic dermatitis with tacrolimus ointment (Protopic, Fujisawa) produced clinical improvement and reduced healthcare resource use and improved patient and caregiver quality of life, said Mark Boguniewicz, M.D., professor, division of pediatric allergy-immunology, National Jewish Medical and Research Center, Denver, and University of Colorado School of Medicine.
Related Videos
Related Content
